Stock data
Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. (KPTI) reported revenue of US$146.07M and net income of -US$196.04M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | US$146.07M | — | -US$90.71M | -US$196.04M | — |
| 2024 | US$145.24M | — | -US$119.44M | -US$76.42M | — |
| 2023 | US$146.03M | — | -US$129.54M | -US$143.10M | — |
| 2022 | US$157.07M | — | -US$142.20M | -US$165.29M | — |
| 2021 | US$209.82M | — | -US$98.27M | -US$124.09M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | US$33.43M | -US$67.02M | — |
| 2026-03-31 | US$35.07M | -US$22.39M | — |
| 2025-12-31 | US$34.08M | -US$102.20M | — |
| 2025-09-30 | US$44.04M | -US$33.13M | — |
| 2025-06-30 | US$37.93M | -US$37.25M | — |
| 2025-03-31 | US$30.02M | -US$23.46M | — |
| 2024-12-31 | US$30.54M | -US$30.78M | — |
| 2024-09-30 | US$38.78M | -US$32.07M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.